Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Carcinoma, Anaplastic 2Thyroid Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

fosbretabulin 2Sorafenib 2Paclitaxel 2Doxorubicin 2tislelizumab 1surufatinib 1pegfilgrastim 1lenvatinib 1efatutazone 1combretastatin 1Radiotherapy 1PLX8394 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Fluorodeoxyglucose F18 1Filgrastim 1Cisplatin 1Carboplatin 1CUDC-907 1Bevacizumab 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Thyroid Carcinoma, Anaplastic × fosbretabulin × Clear all
NCT00507429 2014-06-09

FACT

Mateon Therapeutics

Phase 2/3 Terminated
80 enrolled 10 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00077103 2010-06-11

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡